Clinical Trial

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Name: EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) — clinical trial record (NCT06923761)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EMITT-1

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2025-04-04; most recent amendment 2026-01-26.

Trial Details

NCT Number	NCT06923761
Lead Sponsor	Grey Wolf Therapeutics
Conditions	Advanced Solid Malignancy
Enrollment	300 participants
Start Date	2023-05-21
Primary Completion	2027-04-30 (estimated)
Study Completion	2028-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-28